Edition:
United Kingdom

John Miller

AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys

9:32am GMT

ZURICH U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.

Novartis, GBT sickle cell drugs too expensive, draft U.S. report says

24 Jan 2020

ZURICH Sickle cell disease drugs made by Novartis and Global Blood Therapeutics (GBT) may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S. healthcare affordability.

Novartis, GBT sickle cell drugs too expensive, draft U.S. report says

24 Jan 2020

ZURICH, Jan 24 Sickle cell disease drugs made by Novartis and Global Blood Therapeutics (GBT) may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S. healthcare affordability.

Roche wins approval for cancer drug Kadcyla in fast-growing China market

22 Jan 2020

BEIJING/ZURICH Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another win for the Swiss drugmaker in its second-biggest market where rising demand has helped drive its increased sales and profit.

Clariant's pigments auction due to get under way: sources

22 Jan 2020

FRANKFURT/ZURICH Clariant is reviving the sale of its pigments unit, people familiar with the matter told Reuters, which may fetch up to 900 million Swiss francs ($927.7 million) as the Swiss chemicals maker slims down after failing to combine with peers.

Lonza seeks drug industry veteran as CEO to sharpen pharma focus

21 Jan 2020

ZURICH Lonza aims to hire a drug industry veteran by late May as chief executive, Chairman Albert Baehny said on Tuesday, as the Swiss company sharpens its focus on its fast-growing pharmaceuticals business and off its slumping chemicals unit.

Novartis to speed access to $10 billion heart drug via NHS deal

13 Jan 2020

ZURICH Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021.

Idorsia pairs with Neurocrine in potential $400 million epilepsy drug deal

10 Jan 2020

ZURICH Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that is potentially worth more than $400 million is with U.S.-based Neurocrine Biosciences.

World News